Drugs similar in efficacy for neuropathic pain in diabetes

(HealthDay)—In the treatment of patients with chronic diabetic peripheral neuropathic pain (DPNP), there are no significant differences in pain-relief efficacy between amitriptyline, duloxetine, and pregabalin; however, pregabalin improves sleep continuity and duloxetine improves daytime functioning, according to research published online Sept. 18 in Diabetes Care.

Julia Boyle, Ph.D., of the University of Surrey in the United Kingdom, and colleagues conducted a randomized, double-blind, parallel-group study involving 83 type 1 and type 2 with chronic DPNP who were treated with a placebo run-in followed by 14 days of lower-dose therapy, then 14 days of higher-dose therapy, with either amitriptyline, , or pregabalin. The authors sought to evaluate the impact of these medications on pain, polysomnographic sleep, daytime functioning, and quality of life.

The researchers found that all three medications improved pain compared with placebo, but no statistically significant between-group difference was observed. Pregabalin was associated with improved sleep continuity, while duloxetine increased wake and reduced total . Despite its negative effect on sleep, duloxetine improved arousal and performance on sensory . Pregabalin was associated with a significantly higher number of adverse events compared with the other drugs.

"In conclusion, amitriptyline, duloxetine, and pregabalin were equally effective analgesic medications in patients with DPNP. Daytime function was relatively unaffected by drug treatment, and all three drugs were well tolerated," the authors write. "In this short, 28-day dosing study, there was no evidence of improved quality of life (Short Form 36) even with the sleep enhancement observed with pregabalin."

The study was funded by an investigator-led research grant awarded by Pfizer; two authors disclosed potential financial conflicts of interest.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Low-dose duloxetine deemed safe for urinary incontinence

Jul 27, 2012

(HealthDay) -- Duloxetine appears safe for the routine clinical care of women with stress urinary incontinence (SUI), according to a study published online July 23 in the British Journal of Clinical Pharmacology.

Recommended for you

Blood glucose levels set for achieving HbA1c targets

Apr 11, 2014

(HealthDay)—The average self-monitored blood glucose (SMBG) concentrations needed at premeal, postmeal, and bedtime have been established to achieve a range of hemoglobin A1c (HbA1c) targets, according ...

Women with diabetes less likely to have a mammogram

Apr 11, 2014

Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's ...

Nonalcoholic fatty liver disease linked to CKD in T1DM

Apr 09, 2014

(HealthDay)—For patients with type 1 diabetes, nonalcoholic fatty liver disease (NAFLD) is independently associated with the risk of incident chronic kidney disease (CKD), according to a study published ...

User comments